Literature DB >> 14655005

[Therapy with nonsteroidal anti-inflammatory drugs].

H Bauer1, E Märker-Hermann.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed drugs worldwide. Their analgetic and antiphlogistic effect results from an efficient inhibition of prostaglandin synthesis. The risk of side effects is remarkable. This concerns namely side effects in the gastrointestinal tract and the kidneys. The common NSAIDs inhibit both isoforms of the cyclooxygenase (COX). The analgetic and antiphlogistic effect results from the inhibition of COX-2, whereas the inhibition of COX-1 is responsible for the majority of side effects. If NSAID therapy is necessary, patients at risk should receive an effective prophylaxis, or be treated with COX-2-selective substances. The analgetic effects of COX-2 inhibitors are comparable to common NSAIDs, with a significant reduction of the gastrointestinal risks, except in cases of additional risk factors, e.g., low-dose ASS therapy, etc. In cases of renal impairment both substances should be used with caution, and subtle monitoring is necessary.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14655005     DOI: 10.1007/s00132-003-0559-2

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  24 in total

Review 1.  Renal effects of COX-2-selective inhibitors.

Authors:  D C Brater; C Harris; J S Redfern; B J Gertz
Journal:  Am J Nephrol       Date:  2001 Jan-Feb       Impact factor: 3.754

Review 2.  NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.

Authors:  G Singh; D Rosen Ramey
Journal:  J Rheumatol Suppl       Date:  1998-05

3.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors:  M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

Authors:  N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

6.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Authors:  C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

7.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.

Authors:  J Y Fu; J L Masferrer; K Seibert; A Raz; P Needleman
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

8.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

9.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.

Authors:  M C Allison; A G Howatson; C J Torrance; F D Lee; R I Russell
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more
  3 in total

Review 1.  [Conservative treatment of knee osteoarthritis].

Authors:  H Madry; D Kohn
Journal:  Unfallchirurg       Date:  2004-08       Impact factor: 1.000

2.  [Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid].

Authors:  D Krocker; G Matziolis; J Tuischer; J Funk; S Tohtz; F Buttgereit; C Perka
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

3.  Evaluation of long-term antinociceptive properties of stabilized hyaluronic acid preparation (NASHA) in an animal model of repetitive joint pain.

Authors:  Michael Karl Boettger; Diana Kümmel; Andrew Harrison; Hans-Georg Schaible
Journal:  Arthritis Res Ther       Date:  2011-07-07       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.